|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AlphaRx Inc., of Markham, Ontario, and Proprius Pharmaceuticals Inc., of San Diego, said top-line results from an exploratory Phase II trial of Indaflex 2.5 percent topical indomethacin cream in osteoarthritis of the knee did not meet the primary endpoints. Those were defined as a change from baseline to week six in the global Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score and the subject's global assessment of efficacy - subgroup analysis of patients with moderate to severe pain and more impaired physical function at baseline showed positive trends when treated with Indaflex as compared to placebo or vehicle. The trial enrolled 233 ...